Sign In
Buy FHTX
$4.53
-0.210 (-4.43%)
At Close: Jul 31, 2026
Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences
07:00am, Tuesday, 24'th Feb 2026
WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases b
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Ryan Maynard as Chief Financial Officer
07:00am, Monday, 23'rd Feb 2026
WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases b
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Average Rating of “Buy” from Brokerages
03:24am, Saturday, 14'th Feb 2026
Shares of Foghorn Therapeutics Inc. (NASDAQ: FHTX - Get Free Report) have received a consensus rating of "Buy" from the nine analysts that are presently covering the company, MarketBeat Ratings report
Foghorn Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit
07:00am, Tuesday, 03'rd Feb 2026
WATERTOWN, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases b
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Average Rating of “Buy” from Brokerages
06:13am, Tuesday, 20'th Jan 2026
Foghorn Therapeutics Inc. (NASDAQ: FHTX - Get Free Report) has earned an average recommendation of "Buy" from the nine research firms that are presently covering the firm, MarketBeat.com reports. One
Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff
10:52am, Wednesday, 14'th Jan 2026
/PRNewswire/ -- Equity-Insider.com News Commentary - The precision oncology market is hitting a massive growth spurt, projected to rocket from $110 billion
Foghorn Therapeutics Announces Closing of $50 Million Registered Direct Financing at a 30% Premium
04:05pm, Tuesday, 13'th Jan 2026
WATERTOWN, Mass., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases b
Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026
10:20pm, Friday, 09'th Jan 2026
Recently raised $50 million with BVF Partners, Deerfield Management, founding investor Flagship Pioneering and a leading biotech mutual fund in a transaction that will close January 13 th , 2026
3 Cancer Stocks to Buy Amid Rapid Advances in Cancer Treatment
11:40am, Thursday, 18'th Dec 2025
J&J, ImmunityBio and Foghorn Therapeutics stand out as oncology players amid rapid innovation in cancer care with advancing pipelines, approvals and partnerships.
Estrella Immunopharma (NASDAQ:ESLA) & Foghorn Therapeutics (NASDAQ:FHTX) Head-To-Head Contrast
03:54am, Tuesday, 16'th Dec 2025
Foghorn Therapeutics (NASDAQ: FHTX - Get Free Report) and Estrella Immunopharma (NASDAQ: ESLA - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare th
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Average Recommendation of “Buy” from Analysts
01:27am, Monday, 01'st Dec 2025
Shares of Foghorn Therapeutics Inc. (NASDAQ: FHTX - Get Free Report) have received a consensus recommendation of "Buy" from the eight brokerages that are presently covering the company, MarketBeat Rat
Foghorn Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
07:00am, Tuesday, 25'th Nov 2025
CAMBRIDGE, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases b
Does Foghorn Therapeutics (FHTX) Have the Potential to Rally 133.27% as Wall Street Analysts Expect?
10:57am, Wednesday, 19'th Nov 2025
The mean of analysts' price targets for Foghorn Therapeutics (FHTX) points to a 133.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement
Foghorn Therapeutics Inc. (FHTX) Reports Q3 Loss, Beats Revenue Estimates
09:16am, Wednesday, 05'th Nov 2025
Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to a loss of $0.31 per share a year ago.
Foghorn Therapeutics Provides Third Quarter 2025 Financial and Corporate Update
07:00am, Wednesday, 05'th Nov 2025
Ongoing FHD-909 (LY4050784) Phase 1 dose escalation trial in SMARCA4 (BRG1)-mutated cancer remains on track with non-small cell lung cancer (NSCLC) as the primary target population Selective CBP deg
